BTSG
BrightSpring Health Services, Inc.
$70.17
-0.39 (-0.55%)
At close · Jul 7
Market Cap
$13.61B
Shares
193,918,398
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$70.17
Open$70.78
Day$68.63–71.34
52W$19.01–72.06
Avg vol 30d3.7M
Short int9.4M · 4.8% float · 2.2d
Short vol57%
Last earningsMay 1, 2026
DataJan 2024–Jul 2026
Filing10-Q · May 1
Equibles Rating
blended score · not investment advice
Overall
Neutral
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+64% above
+
Price vs 50-day avg
+17% above
−
RSI (14)
72 · overbought
−
MACD trend
negative
+
52-week position
96% · near high
Sentiment · smart money
Neutral
◦
Trend (MA cross)
50d $60 › 200d $43 — 50d above 200d
+
Institutional flow
8 of 336 funds reported for Jun 30 · net +5.1K sh shares · +5 new
−
Insider flow
Net -$1.7B over 90 days · 100% sells
−
Short interest
4.84% of float · ▲ +8.9% MoM · 2.2 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
336 holders — near 2-yr high, broad support
Fundamentals
Strong
+
Revenue growth
+28% Y/Y
−
Gross margin
12%, contracting
+
EPS growth
+1067% Y/Y
+
Free cash flow
$394.7M
◦
Valuation
P/E 50.1 · in line
−
Balance sheet
net debt $2.4B
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Jul 26, 2026
Est · unconfirmed
· in 3 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 1, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance & track record
Latest guidance
· from the 8-K filed May 1, 2026
Total Adjusted EBITDA
· full year 2026
Non-GAAP
Initiated
$795M – $825M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+64% above
Bullish
Price vs 50-day avg
+17% above
Bullish
RSI (14)
72 · overbought
Bearish
MACD trend
negative
Bearish
52-week position
96% · near high
Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $60 › 200d $43 — 50d above 200d
Institutional flow
Accumulating
8 of 336 funds reported for Jun 30 · net +5.1K sh shares · +5 new
Insider flow
Distributing
Net -$1.7B over 90 days · 100% sells
Short interest
Rising
4.84% of float · ▲ +8.9% MoM · 2.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
336 holders — near 2-yr high, broad support
Price context
position in its 52-week range
52-wk low $19
Now $70 · 96%
52-wk high $72
vs 200-day avg +64%
vs 50-day avg +17%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $190M | Q1 2026 | — |
| Home Health Care average daily census | 46,066 | Q1 2026 | — |
| Leverage | 2.27 | as of March 31, 2026 | -24.1% |
|
|
|||
| Personal Care persons served | 16,079 | Q1 2026 | — |
| Pharmacy Solutions segment EBITDA non-GAAP | $169M | Q1 2026 | — |
| Provider Services segment EBITDA non-GAAP | $66M | Q1 2026 | — |
| Rehab Care persons served | 7,620 | Q1 2026 | — |
| Total Segment Adjusted EBITDA non-GAAP | $235M | Q1 2026 | — |
| adjusted EBITDA margin non-GAAP | 5.3% | Q1 2026 call | — |
| CAPS overall hospice rating | 87% | Q1 2026 call | — |
| cash flow from operations (excluding Community Living divestiture fees) non-GAAP | $123M | Q1 2026 call | — |
| home and community pharmacy dispensing accuracy | 99.99% | Q1 2026 call | — |
| home and community pharmacy on-time delivery | 96% | Q1 2026 call | — |
| home and community pharmacy order completeness | 99% | Q1 2026 call | — |
| Home and Community Rehab patient satisfaction score | 97% | Q1 2026 call | — |
| Home Health Best Home Health provider locations named | 65 | Q1 2026 call | — |
| infusion discharges due to completion of therapy | 97% | Q1 2026 call | — |
| infusion patient satisfaction score | 94% | Q1 2026 call | — |
| limited distribution drugs (total) | 153 | Q1 2026 call | — |
| number of LDDs | 153 | Q1 2026 call | — |
| personal care client satisfaction score | 4.6 | Q1 2026 call | — |
| rehab outpatient patient satisfaction score | 98% | Q1 2026 call | — |
| rehab patient satisfaction (home and community) | 97% | Q1 2026 call | — |
| rehab patient satisfaction (outpatient) | 98% | Q1 2026 call | — |
| specialty pharmacy medication possession ratio | 92.1% | Q1 2026 call | — |
| Specialty Pharmacy time to first fill | 4.6 | Q1 2026 call | — |
| specialty pharmacy time-to-first fill | 4.6 | Q1 2026 call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BTSG
this stock
BrightSpring Health Services, Inc.
|
$13.61B | +87.4% | -0.4% | 50.1 | 4.8% |
|
VEEV
Veeva Systems Inc
|
$31.24B | -13.9% | +28.1% | 34.1 | 4.6% |
|
PMDIY
Pro Medicus Ltd./ADR
|
$15.67B | -9.4% | — | — | 0.0% |
|
TEM
Tempus AI, Inc.
|
$11.21B | +2.8% | +65.8% | — | 21.2% |
|
HQY
Healthequity, Inc.
|
$8.07B | +5.4% | +28.7% | 36.2 | 5.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BTSG | +1.7% | +22.3% | +79.9% | +0.6% | +87.4% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | +0.8% | +20.9% | +72.3% | +0.5% | +77.7% |